Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS0159 DDI and Food Effect Study in Healthy Adults
NCT07429331Phase 1Completed
- Sponsor
- Cascade Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linafexor in Nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) (3 arms), sponsored by Cascade Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Day 9, Area Under the Curve from Time Zero to Last Quantifiable Concentration at Day 9 and 4 more. Started Mar 2026; status: completed.
02
Drugs
linafexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)primary biliary cholangitis (PBC)Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT07429331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429331.